Size of drug patent thickets highlighted by report, amidst intense pharma IP scrutiny

A new report revealing the large number of secondary patents granted, and applied for, by the owners of the US' best-selling drugs is sure to fuel the ongoing controversy over pharma IP rights.


Get unlimited access to all IAM content